Paper Details

  1. Home
  2. Paper Details

Important Group Differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma.

Author: ArondekarBhakti, BushmakinAndrew G, CappelleriJoseph C, CellaDavid, HariharanSubramanian, MotzerRobert J, RamaswamyKrishnan, RiniBrian I

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Between-group differences in FKSI-DRS scores as low as 1 point might be meaningful in patients undergoing treatment for metastatic renal cell carcinoma (mRCC). This was determined using data from two pivotal phase III mRCC trials, with the important difference (ID) ranging between 0.62 and 1.3 points depending on the anchor used.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms (FKSI-DRS) is important to gauge clinical benefit in metastatic renal cell carcinoma (mRCC). OBJECTIVES: To estimate important difference (ID) in FKSI-DRS scores that is considered to be meaningful...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/30502785

データ提供：米国国立医学図書館（NLM）

Measuring the Impact of Treatment on Renal Cell Carcinoma

Metastatic renal cell carcinoma (mRCC) is a type of kidney cancer that can be challenging to treat. This study explores the use of the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms (FKSI-DRS) scale to measure the impact of treatment on patients with mRCC.

Assessing Treatment Effectiveness

The researchers aimed to determine the 'important difference' (ID) in FKSI-DRS scores that is considered meaningful when comparing the effectiveness of different treatments. This is like using a compass to guide the traveler through the desert of cancer treatment, ensuring that the chosen path leads to a meaningful improvement in their well-being.

A Guide for Assessing Treatment Effectiveness

The study found that even a small difference of 1 point in FKSI-DRS scores could be clinically significant. This is like understanding that even subtle changes in the desert landscape, such as a shift in the wind direction, can have a significant impact on the traveler's journey. The study provides valuable guidance for clinicians in interpreting the results of FKSI-DRS scores and assessing the effectiveness of treatment for patients with mRCC.

Dr.Camel's Conclusion

This research highlights the importance of using reliable tools to assess the effectiveness of treatment for cancer patients. It's a reminder that finding the right compass to navigate the desert of disease is crucial for making informed decisions and optimizing patient care. The study emphasizes that even seemingly small differences in symptom scores can have a significant impact on the patient's experience and overall well-being.

Date :
  1. Date Completed 2019-01-02
  2. Date Revised 2019-12-01
Further Info :

Pubmed ID

30502785

DOI: Digital Object Identifier

NIHMS1051892

Related Literature

Article Analysis
・Side Effects of axitinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.